Company Raises Outlook for 2022

  • Q3 Revenue of $16.5 million, up 96% year-over-year
  • Q3 Ending ARR of $28.7 million, up 189% year-over-year
  • Q3 Ending RPO of $109.4 million, up 220% year-over-year
  • Q3 Ending Evolv Express® subscriptions of 1,692, up 198% year-over-year

Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced financial results for its third quarter ended September 30, 20221 and raised its business outlook for 2022.

“We’re pleased to be reporting record third quarter results which were highlighted by strong growth in revenues and continued market expansion,” said Peter George, President and Chief Executive Officer of Evolv Technology. “We experienced particularly robust market adoption with 92 new customers including five of the largest school districts in the United States, over a dozen new hospitals across the nation, as well as the home stadiums of five additional professional sports teams. Our results and momentum position us well to deliver full year growth above our previous outlook for 2022.”

Results for the Third Quarter of 2022

Total revenue for the third quarter of 2022 was $16.5 million, an increase of 96% compared to $8.4 million for the third quarter of 2021. Total Contract Value (“TCV”)2 of orders booked for the third quarter of 2022 was $45.4 million, an increase of 167% compared to $17.0 million in the third quarter of 2021. Annual Recurring Revenue (“ARR”)3 was $28.7 million at the end of third quarter of 2022, an increase of 189% compared to $9.9 million at the end of the third quarter of 2021. Net loss for the third quarter of 2022 was $(18.6) million, or $(0.13) per basic and diluted share, compared to net income attributable to common stockholders for basic and diluted shares of $20.8 million and $21.3 million, respectively, or $0.17 per basic share and $0.14 per diluted share, in the third quarter of 2021. Adjusted earnings (loss)4 for the third quarter of 2022 was $(18.6) million, or $(0.13) per diluted share, compared to adjusted earnings (loss)4 of $(12.9) million, or $(0.08) per diluted share, for the third quarter of 2021. Adjusted EBITDA4 for the third quarter of 2022 was $(18.0) million compared to $(11.5) million in the third quarter of 2021.

Results for the First Nine Months of 2022

Total revenue for the nine months ended September 30, 2022 was $34.3 million, an increase of 104% compared to $16.8 million for the nine months ended September 30, 2021. TCV2 of orders booked for the nine months ended September 30, 2022 was $86.6 million, an increase of 141% compared to $35.9 million for the nine months ended September 30, 2021. Net loss for the nine months ended September 30, 2022 was $(58.1) million, or $(0.40) per basic and diluted share, compared to net loss of $(15.7) million, or $(0.33) per basic and diluted share, for the nine months ended September 30, 2021. Adjusted earnings (loss)4 for the nine months ended September 30, 2022 was $(54.3) million, or $(0.38) per diluted share, compared to $(33.5) million, or $(0.70) per diluted share, for the nine months ended September 30, 2021. Adjusted EBITDA4 for the nine months ended September 30, 2022 was $(51.7) million, compared to $(24.9) million for the nine months ended September 30, 2021.

Company Raises Outlook for 2022

The Company today commented on its business outlook for 2022. The Company's outlook is based on the current indications for its business, which may change at any time.

 

 

2022 Business Outlook

Estimate (In millions)

 

Issued August 10,

2022

 

Issued November 9,

2022

Total Revenue

 

$29-$31

 

$46-$48

Annual Recurring Revenue3 (ARR) at 12/31

 

$27-$28

 

$31-$32

Adjusted EBITDA4

 

($65-$67)

 

No change

Cash and Cash Equivalents

 

$220-$230

 

No change

“We believe we are well positioned to deliver strong top line growth above our previously issued guidance in 2022,” said Mark Donohue, Chief Financial Officer of Evolv Technology. “Our preliminary estimates for 2023 call for exiting ARR in the range of $65 million and $70 million – reflecting growth of more than 100% – and full year revenues in the range of $55 million to $60 million, reflecting our transition towards a subscription model. We also expect to significantly reduce our full year operating cash usage in 2023. We will provide formal detailed guidance for 2023 when we release results for the fourth quarter of 2022.”

Company to Host Live Conference Call and Webcast

The Company’s management team plans to host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss the financial results as well as management’s outlook for the business and other matters. The conference call may be accessed in the United States by dialing +1.877.692.8955 and using access code 774298. The conference call may be accessed outside of the United States by dialing +1.234.720.6979 and using the same access code. The conference call will be simultaneously webcast on the Company’s investor relations website, which can be accessed at http://ir.evolvtechnology.com. A replay of the conference call will be available for a period of 30 days by dialing +1.866.207.1041 or +1.402.970.0847 and using access code 4430069 or by accessing the webcast replay on the Company’s investor relations website at http://ir.evolvtechnology.com.

About Evolv Technology

Evolv Technology (NASDAQ: EVLV) is transforming human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered weapons detection and analytics. Its mission is to transform security to create a safer world to work, learn, and play. Evolv has digitally transformed the gateways in places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than 425 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category. Evolv Technology®, Evolv Express®, Evolv Insights®, and Evolv Cortex AI® are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit https://evolvtechnology.com.

1 Amounts herein pertaining to September 30, 2022 represent a preliminary estimate as of the date of this earnings release. More information on our results of operations for the three and nine months ended September 30, 2022 will be provided upon filing our Quarterly Report on Form 10-Q with the Securities and Exchange Commission.

2 We define Total Contract Value, or TCV, of orders booked as the total value of the contract over the specified term. Our calculation of TCV is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases). TCV should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of TCV may differ from similarly titled metrics presented by other companies. The fourth quarter of the fiscal year ended December 31, 2022 is the final quarter that we will be reporting TCV.

3 We define Annual Recurring Revenue, or ARR, as subscription revenue and the recurring service revenue related to purchase subscriptions for the final month of the quarter normalized to a one-year period. Our calculation of ARR is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases) that may cause any such contract not to be renewed on its existing terms. In addition, the amount of actual revenue that we recognize over any 12-month period is likely to differ from ARR at the beginning of that period, sometimes significantly. This may occur due to new bookings, cancellations, upgrades, downgrades or other changes in pending renewals, as well as the effects of professional services revenue and acquisitions or divestitures. As a result, ARR should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of ARR may differ from similarly titled metrics presented by other companies.

4 Non-GAAP Financial Measures In this press release, the Company’s adjusted operating expenses, adjusted gross profit, adjusted gross margin, adjusted operating income (loss), adjusted EBITDA, adjusted earnings (loss), and adjusted earnings per share-diluted are not presented in accordance with generally accepted accounting principles (GAAP) and are not intended to be used in lieu of GAAP presentations of results of operations. Adjusted gross profit and adjusted gross margin exclude one-time items which management believes provides a more meaningful representation of contribution margin. Adjusted EBITDA is defined as net income (loss) plus depreciation and amortization, share-based compensation, and certain other one-time expenses. Adjusted earnings (loss) is defined as net income (loss) plus stock-based compensation, change in fair value of derivative liability, change in fair value of contingent earn-out liability, change in fair value of contingently issuable common stock liability, change in fair value of public warrant liability, change in fair value of common stock warrant liability, restructuring expenses, loss on impairment of lease equipment, and certain other one-time expenses. Management presents non-GAAP financial measures because it considers them to be important supplemental measures of performance. Management uses non-GAAP financial measures for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and to determine appropriate levels of operating and capital investments. Management also believes non-GAAP financial measures provide additional insight for analysts and investors in evaluating the Company's financial and operational performance. However, non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. We intend to provide non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of non-GAAP financial measures will provide consistency in our financial reporting. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures included in this press release.

Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts should be considered forward-looking statements, including without limitation statements regarding: the transition of our business model, our ability to reduce future cash burn and meet our goals for revenue and profitability, including for fiscal years 2022 and 2023. Forward-looking statements involve the Company’s current expectations and projections relating to its financial condition, competitive position, future financial results, plans, objectives, and business. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “should,” “could,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or the negative of these terms or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect the Company’s current views with respect to future events and the Company’s performance and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation expectations regarding the Company’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures; the Company’s history of losses and lack of profitability; the Company’s reliance on third party contract manufacturing; the rate of innovation required to maintain competitiveness in the markets in which the Company competes; the competitiveness of the market in which the Company competes; the ability for the Company to obtain, maintain, protect and enforce the Company’s intellectual property rights; the concentration of the Company’s revenues on a single solution; the Company’s ability to timely design, produce and launch its solutions, the Company’s ability to invest in growth initiatives and pursue acquisition opportunities; the limited liquidity and trading of the Company’s securities; geopolitical risk and changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; operational risk; risk that the COVID-19 pandemic, including variants, vaccine roll-out efforts, and local, state, and federal responses to addressing the pandemic may have an adverse effect on the Company’s business operations, as well as the Company’s financial condition and results of operations; risks associated with inflation and its possible impact on the Company; litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on resources; and the other important risk factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission ("SEC") on March 28, 2022, as may be updated in other filings we make with the SEC.

These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

EVOLV TECHNOLOGY CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited)

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenue:

 

 

 

 

 

 

 

Product revenue

$

9,839

 

 

$

5,395

 

 

$

19,179

 

 

$

10,279

 

Subscription revenue

 

5,198

 

 

 

2,312

 

 

 

12,208

 

 

 

5,060

 

Service revenue

 

1,493

 

 

 

717

 

 

 

2,923

 

 

 

1,456

 

Total revenue

 

16,530

 

 

 

8,424

 

 

 

34,310

 

 

 

16,795

 

Cost of revenue:

 

 

 

 

 

 

 

Cost of product revenue

 

12,960

 

 

 

2,967

 

 

 

23,513

 

 

 

7,386

 

Cost of subscription revenue

 

2,207

 

 

 

1,277

 

 

 

5,730

 

 

 

3,080

 

Cost of service revenue

 

1,138

 

 

 

713

 

 

 

3,392

 

 

 

1,685

 

Total cost of revenue

 

16,305

 

 

 

4,957

 

 

 

32,635

 

 

 

12,151

 

Gross profit

 

225

 

 

 

3,467

 

 

 

1,675

 

 

 

4,644

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

5,616

 

 

 

3,612

 

 

 

13,947

 

 

 

8,399

 

Sales and marketing

 

11,746

 

 

 

10,024

 

 

 

33,169

 

 

 

17,756

 

General and administrative

 

8,839

 

 

 

7,535

 

 

 

29,268

 

 

 

12,058

 

Loss from impairment of property and equipment

 

626

 

 

 

1,656

 

 

 

1,038

 

 

 

1,656

 

Total operating expenses

 

26,827

 

 

 

22,827

 

 

 

77,422

 

 

 

39,869

 

Loss from operations

 

(26,602

)

 

 

(19,360

)

 

 

(75,747

)

 

 

(35,225

)

Other income (expense), net:

 

 

 

 

 

 

 

Interest expense

 

(188

)

 

 

(295

)

 

 

(489

)

 

 

(5,952

)

Interest income

 

1,052

 

 

 

 

 

 

1,611

 

 

 

 

Other expense, net

 

(57

)

 

 

(669

)

 

 

(57

)

 

 

(669

)

Loss on extinguishment of debt

 

 

 

 

(865

)

 

 

 

 

 

(12,685

)

Change in fair value of derivative liability

 

 

 

 

475

 

 

 

 

 

 

(1,745

)

Change in fair value of contingent earn-out liability

 

7,245

 

 

 

32,609

 

 

 

9,754

 

 

 

32,609

 

Change in fair value of contingently issuable common stock liability

 

1,081

 

 

 

5,718

 

 

 

2,529

 

 

 

5,718

 

Change in fair value of public warrant liability

 

(1,146

)

 

 

3,152

 

 

 

4,297

 

 

 

3,152

 

Change in fair value of common stock warrant liability

 

 

 

 

42

 

 

 

 

 

 

(879

)

Total other income (expense), net

$

7,987

 

 

$

40,167

 

 

$

17,645

 

 

$

19,549

 

Net income (loss) attributable to common stockholders – basic

$

(18,615

)

 

$

20,807

 

 

$

(58,102

)

 

$

(15,676

)

Net income (loss) attributable to common stockholders – diluted

$

(18,615

)

 

$

21,278

 

 

$

(58,102

)

 

$

(15,676

)

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

Basic

 

144,117,273

 

 

 

119,745,196

 

 

 

143,522,555

 

 

 

47,772,253

 

Diluted

 

144,117,273

 

 

 

153,936,436

 

 

 

143,522,555

 

 

 

47,772,253

 

Net income (loss) per share

 

 

 

 

 

 

 

Basic

$

(0.13

)

 

$

0.17

 

 

$

(0.40

)

 

$

(0.33

)

Diluted

$

(0.13

)

 

$

0.14

 

 

$

(0.40

)

 

$

(0.33

)

 

 

 

 

 

 

 

 

Net income (loss)

$

(18,615

)

 

$

20,807

 

 

$

(58,102

)

 

$

(15,676

)

Other comprehensive income (loss)

 

 

 

 

 

 

 

Cumulative translation adjustment

 

45

 

 

 

 

#

 

35

 

#

 

 

Total other comprehensive income

 

45

 

 

 

 

 

 

35

 

 

 

 

Total comprehensive income (loss)

$

(18,570

)

 

$

20,807

 

 

$

(58,067

)

 

$

(15,676

)

EVOLV TECHNOLOGY CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited)

 

September 30,

2022

 

December 31,

2021

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

218,499

 

 

$

307,492

 

Restricted cash

 

400

 

 

 

400

 

Accounts receivable, net

 

21,199

 

 

 

6,477

 

Inventory

 

6,732

 

 

 

2,890

 

Current portion of contract assets

 

5,291

 

 

 

1,459

 

Current portion of commission asset

 

2,413

 

 

 

1,645

 

Prepaid expenses and other current assets

 

20,223

 

 

 

10,757

 

Total current assets

 

274,757

 

 

 

331,120

 

Restricted cash, noncurrent

 

275

 

 

 

275

 

Contract assets, noncurrent

 

1,524

 

 

 

3,418

 

Commission asset, noncurrent

 

4,607

 

 

 

3,719

 

Property and equipment, net

 

40,532

 

 

 

23,783

 

Operating lease right-of-use assets

 

1,882

 

 

 

 

Other assets

 

2,045

 

 

 

542

 

Total assets

$

325,622

 

 

$

362,857

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

11,139

 

 

$

6,045

 

Accrued expenses and other current liabilities

 

8,884

 

 

 

9,551

 

Current portion of deferred revenue

 

15,852

 

 

 

6,599

 

Current portion of deferred rent

 

 

 

 

135

 

Current portion of long-term debt

 

4,000

 

 

 

2,000

 

Current portion of operating lease liabilities

 

1,106

 

 

 

 

Total current liabilities

 

40,981

 

 

 

24,330

 

Deferred revenue, noncurrent

 

9,234

 

 

 

2,475

 

Deferred rent, noncurrent

 

 

 

 

333

 

Long-term debt, noncurrent

 

4,959

 

 

 

7,945

 

Operating lease liabilities, noncurrent

 

1,147

 

 

 

 

Contingent earn-out liability

 

11,452

 

 

 

21,206

 

Contingently issuable common stock liability

 

2,735

 

 

 

5,264

 

Public warrant liability

 

6,733

 

 

 

11,030

 

Total liabilities

 

77,241

 

 

 

72,583

 

 

 

 

 

Stockholders’ equity:

 

 

 

Preferred stock, $0.0001 par value; 100,000,000 authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021

 

 

 

 

 

Common stock, $0.0001 par value; 1,100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 144,434,717 and 142,745,021 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively

 

14

 

 

 

14

 

Additional paid-in capital

 

412,238

 

 

 

396,064

 

Accumulated other comprehensive income

 

35

 

 

 

 

Accumulated deficit

 

(163,906

)

 

 

(105,804

)

Stockholders’ equity

 

248,381

 

 

 

290,274

 

Total liabilities and stockholders’ equity

$

325,622

 

 

$

362,857

 

EVOLV TECHNOLOGY CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)

 

Nine Months Ended

September 30,

 

 

2022

 

 

 

2021

 

Cash flows from operating activities:

 

 

 

Net loss

$

(58,102

)

 

$

(15,676

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

3,782

 

 

 

1,948

 

Write-off of inventory

 

559

 

 

 

400

 

Adjustment to property and equipment for sales type leases

 

(625

)

 

 

 

Loss from impairment of property and equipment

 

1,038

 

 

 

1,656

 

Loss on disposal of property and equipment

 

 

 

 

659

 

Stock-based compensation

 

15,513

 

 

 

6,032

 

Non-cash interest expense

 

14

 

 

 

5,561

 

Non-cash lease expense

 

602

 

 

 

 

Provision recorded for allowance for doubtful accounts

 

100

 

 

 

(63

)

Loss on extinguishment of debt

 

 

 

 

12,685

 

Change in fair value of derivative liability

 

 

 

 

1,745

 

Change in fair value of common stock warrant liability

 

 

 

 

879

 

Change in fair value of earn-out liability

 

(9,754

)

 

 

(32,609

)

Change in fair value of contingently issuable common stock

 

(2,529

)

 

 

(5,718

)

Change in fair value of public warrant liability

 

(4,297

)

 

 

(3,152

)

Changes in operating assets and liabilities

 

 

 

Accounts receivable

 

(14,822

)

 

 

(5,866

)

Inventory

 

(4,401

)

 

 

(736

)

Commission assets

 

(1,656

)

 

 

(1,102

)

Contract assets

 

(1,938

)

 

 

(3,477

)

Other assets

 

(629

)

 

 

23

 

Prepaid expenses and other current assets

 

(9,009

)

 

 

(11,535

)

Accounts payable

 

2,177

 

 

 

240

 

Deferred revenue

 

16,005

 

 

 

2,352

 

Deferred rent

 

 

 

 

397

 

Warranty Reserve

 

 

 

 

(42

)

Accrued expenses and other current liabilities

 

(750

)

 

 

2,834

 

Operating lease liability

 

(699

)

 

 

 

Net cash used in operating activities

 

(69,421

)

 

 

(42,565

)

Cash flows from investing activities:

 

 

 

Development of internal-use software

 

(1,936

)

 

 

 

Purchases of property and equipment

 

(17,554

)

 

 

(10,994

)

Proceeds from sale of property and equipment

 

312

 

 

 

 

Net cash used in investing activities

 

(19,178

)

 

 

(10,994

)

Cash flows from financing activities:

 

 

 

Proceeds from exercise of stock options

 

571

 

 

 

777

 

Proceeds from issuance of common stock from the PIPE Investment

 

 

 

 

300,000

 

Proceeds from the closing of the Merger

 

 

 

 

84,945

 

Payment of offering costs from the closing of the Merger and PIPE Investment

 

 

 

 

(33,968

)

Repayment of financing obligations

 

 

 

 

(359

)

Proceeds from long-term debt, net of issuance costs

 

 

 

 

31,882

 

Repayment of principal on long-term debt

 

(1,000

)

 

 

 

Net cash provided by (used in) financing activities

 

(429

)

 

 

383,277

 

Effect of exchange rate changes on cash and cash equivalents

 

35

 

 

 

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

(88,993

)

 

 

329,718

 

Cash, cash equivalents and restricted cash

 

 

 

Cash, cash equivalents and restricted cash at beginning of period

 

308,167

 

 

 

4,704

 

Cash, cash equivalents and restricted cash at end of period

$

219,174

 

 

$

334,422

 

EVOLV TECHNOLOGY REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (In thousands) (Unaudited)

In preparing the condensed consolidated financial statements as of and for the three and six months ended June 30, 2022, the Company identified various errors in its previously issued financial statements. The identified errors impacted the Company's previously issued 2021 quarterly and annual financial statements and its quarterly financial statements for the three months ended March 31, 2022, and accordingly the Company has made adjustments to the prior period amounts presented herein. A summary of the revisions to certain previously reported financial information impacting amounts presented in this earnings release is as follows (in thousands):

 

Three Months Ended

September 30, 2021

 

Nine Months Ended

September 30, 2021

 

As

Previously

Reported

 

Adjustment

 

As Revised

 

As

Previously

Reported

 

Adjustment

 

As Revised

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Product revenue

$

5,345

 

 

$

50

 

 

$

5,395

 

 

$

10,299

 

 

$

(20

)

 

$

10,279

 

Subscription revenue

 

2,305

 

 

 

7

 

 

 

2,312

 

 

 

5,118

 

 

 

(58

)

 

 

5,060

 

Service revenue

 

717

 

 

 

 

 

 

717

 

 

 

1,429

 

 

 

27

 

 

 

1,456

 

Total revenue

 

8,367

 

 

 

57

 

 

 

8,424

 

 

 

16,846

 

 

 

(51

)

 

 

16,795

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

2,933

 

 

 

34

 

 

 

2,967

 

 

 

7,237

 

 

 

149

 

 

 

7,386

 

Cost of subscription revenue

 

1,086

 

 

 

191

 

 

 

1,277

 

 

 

2,542

 

 

 

538

 

 

 

3,080

 

Cost of service revenue

 

192

 

 

 

521

 

 

 

713

 

 

 

732

 

 

 

953

 

 

 

1,685

 

Total cost of revenue

 

4,211

 

 

 

746

 

 

 

4,957

 

 

 

10,511

 

 

 

1,640

 

 

 

12,151

 

Gross profit

 

4,156

 

 

 

(689

)

 

 

3,467

 

 

 

6,335

 

 

 

(1,691

)

 

 

4,644

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

3,641

 

 

 

(29

)

 

 

3,612

 

 

 

8,330

 

 

 

69

 

 

 

8,399

 

Sales and marketing expense

 

8,510

 

 

 

1,514

 

 

 

10,024

 

 

 

17,284

 

 

 

472

 

 

 

17,756

 

General and administrative

 

6,983

 

 

 

552

 

 

 

7,535

 

 

 

11,162

 

 

 

896

 

 

 

12,058

 

Loss from impairment of property and equipment

 

1,656

 

 

 

 

 

 

1,656

 

 

 

1,656

 

 

 

 

 

 

1,656

 

Total operating expenses

 

20,790

 

 

 

2,037

 

 

 

22,827

 

 

 

38,432

 

 

 

1,437

 

 

 

39,869

 

Loss from operations

 

(16,634

)

 

 

(2,726

)

 

 

(19,360

)

 

 

(32,097

)

 

 

(3,128

)

 

 

(35,225

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

(286

)

 

 

(9

)

 

 

(295

)

 

 

(5,988

)

 

 

36

 

 

 

(5,952

)

Other expense, net

 

(669

)

 

 

 

 

 

(669

)

 

 

(669

)

 

 

 

 

 

(669

)

Loss on extinguishment of debt

 

(865

)

 

 

 

 

 

(865

)

 

 

(12,685

)

 

 

 

 

 

(12,685

)

Change in fair value of derivative liability

 

475

 

 

 

 

 

 

475

 

 

 

(1,745

)

 

 

 

 

 

(1,745

)

Change in fair value of contingent earn-out liability

 

31,818

 

 

 

791

 

 

 

32,609

 

 

 

31,818

 

 

 

791

 

 

 

32,609

 

Change in fair value of contingently issuable common stock liability

 

5,718

 

 

 

 

 

 

5,718

 

 

 

5,718

 

 

 

 

 

 

5,718

 

Change in fair value of public warrant liability

 

3,152

 

 

 

 

 

 

3,152

 

 

 

3,152

 

 

 

 

 

 

3,152

 

Change in fair value of common stock warrant liability

 

42

 

 

 

 

 

 

42

 

 

 

(879

)

 

 

 

 

 

(879

)

Total other income (expense), net

 

39,385

 

 

 

782

 

 

 

40,167

 

 

 

18,722

 

 

 

827

 

 

 

19,549

 

Net income (loss) attributable to common stockholders - basic

$

22,751

 

 

$

(1,944

)

 

$

20,807

 

 

$

(13,375

)

 

$

(2,301

)

 

$

(15,676

)

Net income (loss) attributable to common stockholders - diluted

$

23,222

 

 

$

(1,944

)

 

$

21,278

 

 

$

(13,375

)

 

$

(2,301

)

 

$

(15,676

)

 

December 31, 2021

 

As Previously

Reported

Adjustment

As Revised

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

307,492

 

$

 

$

307,492

 

Restricted cash

 

400

 

 

 

 

400

 

Accounts receivable, net

 

6,477

 

 

 

 

6,477

 

Inventory

 

5,140

 

 

(2,250

)

 

2,890

 

Current portion of contract assets

 

1,459

 

 

 

 

1,459

 

Current portion of commission asset

 

1,645

 

 

 

 

1,645

 

Prepaid expenses and other current assets

 

11,047

 

 

(290

)

 

10,757

 

Total current assets

 

333,660

 

 

(2,540

)

 

331,120

 

Restricted cash, noncurrent

 

275

 

 

 

 

275

 

Contract assets, noncurrent

 

3,418

 

 

 

 

3,418

 

Commission asset, noncurrent

 

3,719

 

 

 

 

3,719

 

Property and equipment, net

 

21,592

 

 

2,191

 

 

23,783

 

Other assets

 

401

 

 

141

 

 

542

 

Total assets

$

363,065

 

$

(208

)

$

362,857

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

6,363

 

$

(318

)

$

6,045

 

Accrued expenses and other current liabilities

 

9,183

 

 

368

 

 

9,551

 

Current portion of deferred revenue

 

6,690

 

 

(91

)

 

6,599

 

Current portion of deferred rent

 

135

 

 

 

 

135

 

Current portion of long-term debt

 

2,000

 

 

 

 

2,000

 

Total current liabilities

 

24,371

 

 

(41

)

 

24,330

 

Deferred revenue, noncurrent

 

2,475

 

 

 

 

2,475

 

Deferred rent, noncurrent

 

333

 

 

 

 

333

 

Long-term debt, noncurrent

 

7,945

 

 

 

 

7,945

 

Contingent earn-out liability

 

20,809

 

 

397

 

 

21,206

 

Contingently issuable common stock liability

 

5,264

 

 

 

 

5,264

 

Public warrant liability

 

11,030

 

 

 

 

11,030

 

Total liabilities

 

72,227

 

 

356

 

 

72,583

 

 

 

 

 

Stockholders’ equity:

 

 

 

Convertible preferred stock

 

 

 

 

 

 

Common stock

 

14

 

 

 

 

14

 

Additional paid-in capital

 

395,563

 

 

501

 

 

396,064

 

Accumulated deficit

 

(104,739

)

 

(1,065

)

 

(105,804

)

Stockholders’ equity

 

290,838

 

 

(564

)

 

290,274

 

Total liabilities and stockholders’ equity

$

363,065

 

$

(208

)

$

362,857

 

EVOLV TECHNOLOGY RECONCILIATION OF FORECASTED 2022 NET LOSS TO ADJUSTED EBITDA (In thousands) (Unaudited)

 

Twelve Months Ended

December 31, 2022

 

High

 

Low

Net income (loss)

$

(76,000

)

 

$

(78,000

)

Adjustments to reconcile net income (loss) to Adjusted EBITDA:

 

 

 

Depreciation and amortization

 

5,000

 

 

 

5,000

 

Stock-based compensation

 

19,000

 

 

 

19,000

 

Other one-time expenses

 

5,000

 

 

 

5,000

 

Other (income) expense

 

(18,000

)

 

 

(18,000

)

Adjusted EBITDA

$

(65,000

)

 

$

(67,000

)

EVOLV TECHNOLOGY SUMMARY OF KEY OPERATING STATISTICS (Unaudited)

 

Three Months Ended or as of,

($ in thousands)

 

March 31,

2021

 

June 30,

2021

 

September 30,

2021

 

December 31,

2021

 

March 31,

2022

 

June 30,

2022

 

September 30,

2022

New customers

 

 

13

 

 

21

 

 

23

 

 

27

 

 

44

 

 

53

 

 

92

Total contract value of orders booked

 

$

8,424

 

 

$

10,476

 

 

$

16,995

 

 

$

17,916

 

 

$

19,167

 

 

$

22,066

 

 

$

45,353

 

Annual recurring revenue

 

$

5,424

 

 

$

7,423

 

 

$

9,932

 

 

$

12,907

 

 

$

16,641

 

 

$

20,865

 

 

$

28,741

 

Remaining performance obligation

 

$

17,658

 

 

$

24,930

 

 

$

34,152

 

 

$

51,430

 

 

$

63,750

 

 

$

80,978

 

 

$

109,407

 

Net additions

 

 

64

 

 

 

113

 

 

 

176

 

 

 

136

 

 

 

207

 

 

 

237

 

 

 

545

 

Ending deployed units

 

 

278

 

 

 

391

 

 

 

567

 

 

 

703

 

 

 

910

 

 

 

1,147

 

 

 

1,692

 

EVOLV TECHNOLOGY RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES (In thousands) (Unaudited)

 

Three Months Ended,

 

 

March 31,

2021

 

June 30,

2021

 

September 30,

2021

 

December 31,

2021

 

March 31,

2022

 

June 30,

2022

 

September 30,

2022

Operating expenses, GAAP

 

$

9,400

 

 

$

7,642

 

 

$

22,826

 

 

$

19,429

 

 

$

24,760

 

 

$

25,835

 

 

$

26,827

 

Stock-based compensation(1)

 

 

(300

)

 

 

(1,052

)

 

 

(4,589

)

 

 

(3,513

)

 

 

(3,819

)

 

 

(4,781

)

 

 

(6,298

)

Restructuring expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(324

)

 

 

13

 

 

 

 

Loss on impairment of lease equipment

 

 

 

 

 

 

 

 

(1,656

)

 

 

(213

)

 

 

(96

)

 

 

(316

)

 

 

(626

)

Other one-time expenses

 

 

 

 

 

 

 

 

(685

)

 

 

 

 

 

(1,107

)

 

 

(2,298

)

 

 

(69

)

Adjusted Operating Expenses

 

$

9,100

 

 

$

6,590

 

 

$

15,896

 

 

$

15,703

 

 

$

19,414

 

 

$

18,453

 

 

$

19,834

 

(1) Reflects immaterial adjustments to previously reported stock-based compensation amounts.

EVOLV TECHNOLOGY RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED GROSS PROFIT AND GAAP OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS) (In thousands) (Unaudited)

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

2022

 

2021

 

2022

 

2021

Revenue

$

16,530

 

 

$

8,424

 

 

$

34,310

 

 

$

16,795

 

Cost of revenue

 

16,305

 

 

 

4,957

 

 

 

32,635

 

 

 

12,151

 

Gross Profit, GAAP

 

225

 

 

 

3,467

 

 

 

1,675

 

 

 

4,644

 

Stock-based compensation(2)

 

227

 

 

 

66

 

 

 

615

 

 

 

91

 

Amortization of capitalized stock-based compensation

 

6

 

 

 

 

 

 

15

 

 

 

 

Adjusted Gross Profit

$

458

 

 

$

3,533

 

 

$

2,305

 

 

$

4,735

 

 

 

 

 

 

 

 

 

Gross Margin %

 

1.4

%

 

 

41.2

%

 

 

4.9

%

 

 

27.7

%

Adjusted Gross Margin %

 

2.8

%

 

 

41.9

%

 

 

6.7

%

 

 

28.2

%

(2) Reflects immaterial adjustments to previously reported stock-based compensation amounts.

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Operating income (loss), GAAP

$

(26,602

)

 

$

(19,360

)

 

$

(75,747

)

 

$

(35,225

)

Stock-based compensation

 

6,525

 

 

 

4,655

 

 

 

15,513

 

 

 

6,032

 

Amortization of capitalized stock-based compensation

 

6

 

 

 

 

 

 

15

 

 

 

 

Restructuring expenses

 

 

 

 

 

 

 

311

 

 

 

 

Loss on impairment of lease equipment

 

626

 

 

 

1,656

 

 

 

1,038

 

 

 

1,656

 

Other one-time expenses

 

69

 

 

 

685

 

 

 

3,474

 

 

 

685

 

Adjusted Operating Income (loss)

$

(19,376

)

 

$

(12,364

)

 

$

(55,396

)

 

$

(26,852

)

EVOLV TECHNOLOGY RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA (In thousands) (Unaudited)

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Net income (loss)

$

(18,615

)

 

$

20,807

 

 

$

(58,102

)

 

$

(15,676

)

Depreciation & amortization

 

1,432

 

 

 

846

 

 

 

3,782

 

 

 

1,948

 

Stock-based compensation

 

6,525

 

 

 

4,655

 

 

 

15,513

 

 

 

6,032

 

Interest expense (income)

 

(864

)

 

 

295

 

 

 

(1,122

)

 

 

5,952

 

Loss on disposal of property & equipment

 

 

 

 

659

 

 

 

 

 

 

659

 

Loss on extinguishment of debt

 

 

 

 

865

 

 

 

 

 

 

12,685

 

Change in fair value of derivative liability

 

 

 

 

(475

)

 

 

 

 

 

1,745

 

Change in fair value of contingent earn-out liability

 

(7,245

)

 

 

(32,609

)

 

 

(9,754

)

 

 

(32,609

)

Change in fair value of contingently issuable common stock liability

 

(1,081

)

 

 

(5,718

)

 

 

(2,529

)

 

 

(5,718

)

Change in fair value of public warrant liability

 

1,146

 

 

 

(3,152

)

 

 

(4,297

)

 

 

(3,152

)

Change in fair value of common stock warrant liability

 

 

 

 

(42

)

 

 

 

 

 

879

 

Restructuring expenses

 

 

 

 

 

 

 

311

 

 

 

 

Loss on impairment of lease equipment

 

626

 

 

 

1,656

 

 

 

1,038

 

 

 

1,656

 

Other one-time expenses

 

69

 

 

 

685

 

 

 

3,474

 

 

 

685

 

Adjusted EBITDA

$

(18,007

)

 

$

(11,528

)

 

$

(51,686

)

 

$

(24,914

)

EVOLV TECHNOLOGY RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EARNINGS (LOSS) (In thousands, except share and per share data) (Unaudited)

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Net income (loss) attributable to common stockholders – diluted

$

(18,615

)

 

$

21,278

 

 

$

(58,102

)

 

$

(15,676

)

Stock-based compensation

 

6,525

 

 

 

4,655

 

 

 

15,513

 

 

 

6,032

 

Amortization of capitalized stock-based compensation

 

6

 

 

 

 

 

 

15

 

 

 

 

Loss on extinguishment of debt

 

 

 

 

865

 

 

 

 

 

 

12,685

 

Change in fair value of derivative liability

 

 

 

 

(475

)

 

 

 

 

 

1,745

 

Change in fair value of contingent earn-out liability

 

(7,245

)

 

 

(32,609

)

 

 

(9,754

)

 

 

(32,609

)

Change in fair value of contingently issuable common stock liability

 

(1,081

)

 

 

(5,718

)

 

 

(2,529

)

 

 

(5,718

)

Change in fair value of public warrant liability

 

1,146

 

 

 

(3,152

)

 

 

(4,297

)

 

 

(3,152

)

Change in fair value of common stock warrant liability

 

 

 

 

(42

)

 

 

 

 

 

879

 

Restructuring expenses

 

 

 

 

 

 

 

311

 

 

 

 

Loss on impairment of lease equipment

 

626

 

 

 

1,656

 

 

 

1,038

 

 

 

1,656

 

Other one-time expenses

 

69

 

 

 

685

 

 

 

3,474

 

 

 

685

 

Adjusted earnings (loss) attributable to common stockholders - diluted

$

(18,569

)

 

$

(12,857

)

 

$

(54,331

)

 

$

(33,473

)

 

 

 

 

 

 

 

 

Weighted average common shares outstanding – diluted

 

144,117,273

 

 

 

153,936,436

 

 

 

143,522,555

 

 

 

47,772,253

 

 

 

 

 

 

 

 

 

Adjusted Earnings Per Share – diluted

$

(0.13

)

 

$

(0.08

)

 

$

(0.38

)

 

$

(0.70

)

 

Investor Relations: Brian Norris Vice President of Finance and Investor Relations bnorris@evolvtechnology.com

Evolv Technologies (NASDAQ:EVLV)
Gráfico Histórico do Ativo
De Dez 2022 até Jan 2023 Click aqui para mais gráficos Evolv Technologies.
Evolv Technologies (NASDAQ:EVLV)
Gráfico Histórico do Ativo
De Jan 2022 até Jan 2023 Click aqui para mais gráficos Evolv Technologies.